279 related articles for article (PubMed ID: 26633641)
41. Short Communication: Association of Vitamin D Insufficiency and Protective Tenofovir Diphosphate Concentrations with Bone Toxicity in Adolescent Boys and Young Men Using Tenofovir Disoproxil Fumarate/Emtricitabine for HIV Pre-Exposure Prophylaxis.
Havens PL; Tamhane A; Stephensen CB; Schuster GU; Gordon CM; Liu N; Wilson CM; Hosek SG; Anderson PL; Kapogiannis BG; Mulligan K
AIDS Res Hum Retroviruses; 2019 Feb; 35(2):123-128. PubMed ID: 30280906
[TBL] [Abstract][Full Text] [Related]
42. Acceptability, safety, and patterns of use of oral tenofovir disoproxil fumarate and emtricitabine for HIV pre-exposure prophylaxis in South African adolescents: an open-label single-arm phase 2 trial.
Gill K; Johnson L; Dietrich J; Myer L; Marcus R; Wallace M; Pidwell T; Mendel E; Fynn L; Jones K; Wiesner L; Slack C; Strode A; Spiegel H; Hosek S; Rooney J; Gray G; Bekker LG
Lancet Child Adolesc Health; 2020 Dec; 4(12):875-883. PubMed ID: 33222803
[TBL] [Abstract][Full Text] [Related]
43. Ex-vivo rectal tissue infection with HIV-1 to assess time to protection following oral preexposure prophylaxis with tenofovir disoproxil/emtricitabine.
Chawki S; Goldwirt L; Mouhebb ME; Gabassi A; Taouk M; Bichard I; Loze B; Amara A; Brand R; Siegel A; McGowan I; Costagliola D; Assoumou L; Molina JM; Delaugerre C;
AIDS; 2024 Mar; 38(4):455-464. PubMed ID: 37976073
[TBL] [Abstract][Full Text] [Related]
44. Pre-Exposure Prophylaxis for HIV Prevention in Women: Current Status and Future Directions.
Hodges-Mameletzis I; Fonner VA; Dalal S; Mugo N; Msimanga-Radebe B; Baggaley R
Drugs; 2019 Aug; 79(12):1263-1276. PubMed ID: 31309457
[TBL] [Abstract][Full Text] [Related]
45. Estimating efficacy in a randomized trial with product nonadherence: application of multiple methods to a trial of preexposure prophylaxis for HIV prevention.
Murnane PM; Brown ER; Donnell D; Coley RY; Mugo N; Mujugira A; Celum C; Baeten JM;
Am J Epidemiol; 2015 Nov; 182(10):848-56. PubMed ID: 26487343
[TBL] [Abstract][Full Text] [Related]
46. HPTN 083-02: factors influencing adherence to injectable PrEP and retention in an injectable PrEP study.
Psaros C; Goodman GR; Lee JS; Rice W; Kelley CF; Oyedele T; Coelho LE; Phanuphak N; Singh Y; Middelkoop K; Griffith S; McCauley M; Rooney J; Rinehart AR; Clark J; Go V; Sugarman J; Fields SD; Adeyeye A; Grinsztejn B; Landovitz RJ; Safren SA;
J Int AIDS Soc; 2024 May; 27(5):e26252. PubMed ID: 38783534
[TBL] [Abstract][Full Text] [Related]
47. Statistical issues in trials of preexposure prophylaxis.
Dunn DT; Glidden DV
Curr Opin HIV AIDS; 2016 Jan; 11(1):116-21. PubMed ID: 26545264
[TBL] [Abstract][Full Text] [Related]
48. Using the adherence-efficacy relationship of emtricitabine and tenofovir disoproxil fumarate to calculate background hiv incidence: a secondary analysis of a randomized, controlled trial.
Glidden DV; Das M; Dunn DT; Ebrahimi R; Zhao Y; Stirrup OT; Baeten JM; Anderson PL
J Int AIDS Soc; 2021 May; 24(5):e25744. PubMed ID: 34021709
[TBL] [Abstract][Full Text] [Related]
49. Phase I trial of pod-intravaginal rings delivering antiretroviral agents for HIV-1 prevention: Rectal drug exposure from vaginal dosing with tenofovir disoproxil fumarate, emtricitabine, and maraviroc.
Vincent KL; Moss JA; Marzinke MA; Hendrix CW; Anton PA; Gunawardana M; Dawson LN; Olive TJ; Pyles RB; Baum MM
PLoS One; 2018; 13(8):e0201952. PubMed ID: 30133534
[TBL] [Abstract][Full Text] [Related]
50. Daily and Nondaily Oral Preexposure Prophylaxis in Men and Transgender Women Who Have Sex With Men: The Human Immunodeficiency Virus Prevention Trials Network 067/ADAPT Study.
Grant RM; Mannheimer S; Hughes JP; Hirsch-Moverman Y; Loquere A; Chitwarakorn A; Curlin ME; Li M; Amico KR; Hendrix CW; Anderson PL; Dye BJ; Marzinke MA; Piwowar-Manning E; McKinstry L; Elharrar V; Stirratt M; Rooney JF; Eshleman SH; McNicholl JM; van Griensven F; Holtz TH
Clin Infect Dis; 2018 May; 66(11):1712-1721. PubMed ID: 29420695
[TBL] [Abstract][Full Text] [Related]
51. Brief Report: Urine Emtricitabine and Tenofovir Concentrations Provide Markers of Recent Antiretroviral Drug Exposure Among HIV-Negative Men Who Have Sex With Men.
Haaland RE; Martin A; Livermont T; Fountain J; Dinh C; Holder A; Lupo LD; Hall L; Conway-Washington C; Kelley CF
J Acquir Immune Defic Syndr; 2019 Nov; 82(3):252-256. PubMed ID: 31335590
[TBL] [Abstract][Full Text] [Related]
52. Decline in Bone Mass With Tenofovir Disoproxil Fumarate/Emtricitabine Is Associated With Hormonal Changes in the Absence of Renal Impairment When Used by HIV-Uninfected Adolescent Boys and Young Men for HIV Preexposure Prophylaxis.
Havens PL; Stephensen CB; Van Loan MD; Schuster GU; Woodhouse LR; Flynn PM; Gordon CM; Pan CG; Rutledge B; Liu N; Wilson CM; Hazra R; Hosek SG; Anderson PL; Seifert SM; Kapogiannis BG; Mulligan K;
Clin Infect Dis; 2017 Feb; 64(3):317-325. PubMed ID: 28013265
[TBL] [Abstract][Full Text] [Related]
53. Single oral dose for HIV pre or post-exposure prophylaxis: user desirability and biological efficacy in macaques.
Massud I; Ruone S; Zlotorzynska M; Haaland R; Mills P; Cong ME; Kelley K; Johnson R; Holder A; Dinh C; Khalil G; Pan Y; Kelley CF; Sanchez T; Heneine W; García-Lerma JG
EBioMedicine; 2020 Aug; 58():102894. PubMed ID: 32707451
[TBL] [Abstract][Full Text] [Related]
54. Low Risk of Proximal Tubular Dysfunction Associated With Emtricitabine-Tenofovir Disoproxil Fumarate Preexposure Prophylaxis in Men and Women.
Mugwanya K; Baeten J; Celum C; Donnell D; Nickolas T; Mugo N; Branch A; Tappero J; Kiarie J; Ronald A; Yin M; Wyatt C;
J Infect Dis; 2016 Oct; 214(7):1050-7. PubMed ID: 27029778
[TBL] [Abstract][Full Text] [Related]
55. Oral antiretroviral chemoprophylaxis: current status.
Baeten J; Celum C
Curr Opin HIV AIDS; 2012 Nov; 7(6):514-9. PubMed ID: 22964886
[TBL] [Abstract][Full Text] [Related]
56. Adherence to event-driven HIV PrEP among men who have sex with men in Amsterdam, the Netherlands: analysis based on online diary data, 3-monthly questionnaires and intracellular TFV-DP.
Jongen VW; Hoornenborg E; van den Elshout MA; Boyd A; Zimmermann HM; Coyer L; Davidovich U; Anderson PL; de Vries HJ; Prins M; Schim van der Loeff MF;
J Int AIDS Soc; 2021 May; 24(5):e25708. PubMed ID: 33973373
[TBL] [Abstract][Full Text] [Related]
57. Bone mineral density changes among HIV-uninfected young adults in a randomised trial of pre-exposure prophylaxis with tenofovir-emtricitabine or placebo in Botswana.
Kasonde M; Niska RW; Rose C; Henderson FL; Segolodi TM; Turner K; Smith DK; Thigpen MC; Paxton LA
PLoS One; 2014; 9(3):e90111. PubMed ID: 24625530
[TBL] [Abstract][Full Text] [Related]
58. Daily oral tenofovir and emtricitabine-tenofovir preexposure prophylaxis reduces herpes simplex virus type 2 acquisition among heterosexual HIV-1-uninfected men and women: a subgroup analysis of a randomized trial.
Celum C; Morrow RA; Donnell D; Hong T; Hendrix CW; Thomas KK; Fife KH; Nakku-Joloba E; Mujugira A; Baeten JM;
Ann Intern Med; 2014 Jul; 161(1):11-9. PubMed ID: 24979446
[TBL] [Abstract][Full Text] [Related]
59. A polyvalent Clade B virus-like particle HIV vaccine combined with partially protective oral preexposure prophylaxis prevents simian-human immunodeficiency virus Infection in macaques and primes for virus-amplified immunity.
Ross TM; Pereira LE; Luckay A; McNicholl JM; García-Lerma JG; Heneine W; Eugene HS; Pierce-Paul BR; Zhang J; Hendry RM; Smith JM
AIDS Res Hum Retroviruses; 2014 Nov; 30(11):1072-81. PubMed ID: 24914761
[TBL] [Abstract][Full Text] [Related]
60. Safety and Feasibility of Antiretroviral Preexposure Prophylaxis for Adolescent Men Who Have Sex With Men Aged 15 to 17 Years in the United States.
Hosek SG; Landovitz RJ; Kapogiannis B; Siberry GK; Rudy B; Rutledge B; Liu N; Harris DR; Mulligan K; Zimet G; Mayer KH; Anderson P; Kiser JJ; Lally M; Brothers J; Bojan K; Rooney J; Wilson CM
JAMA Pediatr; 2017 Nov; 171(11):1063-1071. PubMed ID: 28873128
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
